bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figure S6 from Rational Combination of Immunotherapies with Clinical Efficacy in Mice with Advanced Cancer
Authors: Bransi Ali , Salgado Oscar Camilo , Beffinger Michal , Milo Karim , Silina Karina , Yagita Hideo , Becher Burkhard , Knuth Alexander , van den Broek Maries
Published: April 2023

Tumor growth curves of subcutaneous B16 melanoma.
Supplementary Materials and Methods, Supplementary Figures 1 through 4, and Supplementary Tables 1 and 2 from Expression of the MHC Class II Pathway in Triple-Negative Breast Cancer Tumor Cells Is Associated with a Good Prognosis and Infiltrating Lymphocytes
Authors: Forero Andres , Li Yufeng , Chen Dongquan , Grizzle William E. , Updike Katherine L. , Merz Natalie D. , Downs-Kelly Erinn , Burwell Todd C. , Vaklavas Christos , Buchsbaum Donald J. , Myers Richard M. , LoBuglio Albert F. , Varley Katherine E.
Published: April 2023

This file contains: Supplementary Methods for Tissue Processing, RNA-seq, RNA-seq analysis, and Immunohistochemistry. Supplementary Figure 1: Overlap between clusters identified in our data and TNBC subtypes described in previous studies. Supplementary Figure 2: Heatmap of the normalized gene expression values of each of the 24 prognostic genes in each of the 47 patient's tumors. Supplementary Figure 3: Illustration of TNBC prognostic genes in the MHC II pathway. Supplementary Figure 4: Kaplan-Meier PFS curves of patients with expression levels (tertiles) of CIITA and CD74. Supplementary Table 1: Gene Expression Cluster Content and Outcomes Supplementary Table 2: Correlation Coefficient and Hazard Ratio of MHCII Genes
Supplementary Figure Legends from Prolonged Benefit from Ipilimumab Correlates with Improved Outcomes from Subsequent Pembrolizumab
Authors: Shreders Amanda , Joseph Richard , Peng Chengwei , Ye Fei , Zhao Shilin , Puzanov Igor , Sosman Jeffrey A. , Johnson Douglas B.
Published: April 2023

Legends for supplementary figures 1-3
Supplementary Figure S1 from Rational Combination of Immunotherapies with Clinical Efficacy in Mice with Advanced Cancer
Authors: Bransi Ali , Salgado Oscar Camilo , Beffinger Michal , Milo Karim , Silina Karina , Yagita Hideo , Becher Burkhard , Knuth Alexander , van den Broek Maries
Published: April 2023

Agonistic anti-CD40 supports effector function of adoptively transferred tumor-specific TCR-I cells.
Supplementary Figure 4 from Inhibition of Soluble Tumor Necrosis Factor Prevents Chemically Induced Carcinogenesis in Mice
Authors: Sobo-Vujanovic Andrea , Vujanovic Lazar , DeLeo Albert B. , Concha-Benavente Fernando , Ferris Robert L. , Lin Yan , Vujanovic Nikola L.
Published: April 2023

Gating strategy for STAT3 single-color flow cytometry analysis of splenic monocytes and granulocytes. Splenocytes were fixed, permeabilized, stained with IgG control or anti-pSTAT3 antibodies, and gated similarly as shown in Suppl. Fig. 1, Gate 2: Gate 1, single cells; Gate 2, large non-granular (Monocytes) and granular (Granulocytes) splenocytes; Gate 3 and Gate 4, single-color flow cytometry analysis of monocytes and granulocytes, respectively, for intracellular staining with isotype control (Control), anti-pSTAT3y705 or pSTAT3s727 mAbs.
Supplementary Tables 1 through 4 and Supplementary Figures 1 through 8 from Kinase Regulation of Human MHC Class I Molecule Expression on Cancer Cells
Authors: Brea Elliott J. , Oh Claire Y. , Manchado Eusebio , Budhu Sadna , Gejman Ron S. , Mo George , Mondello Patrizia , Han James E. , Jarvis Casey A. , Ulmert David , Xiang Qing , Chang Aaron Y. , Garippa Ralph J. , Merghoub Taha , Wolchok Jedd D. , Rosen Neal , Lowe Scott W. , Scheinberg David A.
Published: April 2023

Supplementary Table S1. MSK Memorial Hospital IMPACT genomic sequencing data for the JMN human mesothelioma cell line. Supplementary Table S2. Sh RNA used. Supplementary Table S3. List of antibodies used. Supplementary Table S4. Top 5 negative regulatory and top 5 positive regulatory kinase genes that were hits from the screen for regulating surface HLA-A expression. Supplementary Figure S1. Knockdown of HLA-A causes resistance to antibody dependent cellular cytotoxicity by the ESK-M mAb. Supplementary Figure S2. Coordinated regulation of total surface HLA-A, B, and C with knockdown of either MAP2K1 of EGFR. Supplementary Figure S3. Validation of MAP2K1, EGFR, and RET as negative kinase regulators in mesothelioma cell lines. Supplementary Figure S4. DDR2 and MINK1 acts as positive regulators of surface HLA-A. Supplementary Figure S5. Treatment with IFN gamma and/or kinase inhibitors, afatinib or trametinib, on cells with mutant EFGR (H1975) or mutant BRAF (SK-Mel5 and UACC257). Supplementary Figure S6. Viability of JMN after treatment with MEKi trametinib and EGFRi Afatinib. Supplementary Figure S7. Titration of trametinib to determine optimal inhibition of MEK using pERK as a marker of inhibition. Supplementary Figure S8. JMN was treated with 50 nM trametinib and lysate was analyzed as in Figure 4C at different time points.
Supplementary Tables 1 through 3 and Supplementary Figures 1 through 4 from Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade
Authors: Johnson Douglas B. , Frampton Garrett M. , Rioth Matthew J. , Yusko Erik , Xu Yaomin , Guo Xingyi , Ennis Riley C. , Fabrizio David , Chalmers Zachary R. , Greenbowe Joel , Ali Siraj M. , Balasubramanian Sohail , Sun James X. , He Yuting , Frederick Dennie T. , Puzanov Igor , Balko Justin M. , Cates Justin M. , Ross Jeffrey S. , Sanders Catherine , Robins Harlan , Shyr Yu , Miller Vincent A. , Stephens Philip J. , Sullivan Ryan J. , Sosman Jeffrey A. , Lovly Christine M.
Published: April 2023

Supplementary Table 1: Results for samples obtained (less than or equal to) 12 months prior to therapy (optimal) vs. those obtained >12 months from treatment or shortly after starting therapy (non-optimal). Supplementary Table 2: Cox proportional hazards model of OS adjusting for baseline variables. Supplementary Table 3: Cox proportional hazards model of PFS adjusting for baseline variables. Figure S1: (A) Performance of mutational load across a range of potential thresholds. (B) Receiver Operating Curve (ROC) for mutational loads cutoffs of 3.3 mutations/MB (low mutational load group) and 23.1 mutations/MB (high mutational load group). Figure S2: (A) Mutational load in tumors with cutaneous/unknown primaries in responders vs. non-responders. (B) Mutational load in tumors with non-cutaneous primaries (acral, mucosal, uveal) in responders vs. non-responders. (C) Gene amplifications and deletions in responders vs. non-responders. Figure S3: (A) LRP1B mutations/variants of unknown significance in responders vs. non-responders. (B) Total number of mutations among melanomas with and without LRP1B mutations. (C) Association between number of LRP1B mutations and total mutations in the melanoma TCGA. Figure S4: (A) T cell receptor (TCR) clonality in responders vs. non-responders. (B) T cell fraction in responders vs. non-responders. (C) TCR clonality in responders vs. non-responders in ideal samples, defined as those obtained within 4 months of anti-PD-1/PD-L1 treatment without other prior therapies. (D) T cell fraction in these ideal samples. Figure S5: Mutation load correlated with (A) T cell receptor (TCR) clonality and (B) T cell fraction.
Supplementary Figure Legends from In Vitro Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and In Vivo Toxicology in Non-Human Primates
Authors: Wang Changyu , Thudium Kent B. , Han Minhua , Wang Xi-Tao , Huang Haichun , Feingersh Diane , Garcia Candy , Wu Yi , Kuhne Michelle , Srinivasan Mohan , Singh Sujata , Wong Susan , Garner Neysa , Leblanc Heidi , Bunch R. Todd , Blanset Diann , Selby Mark J. , Korman Alan J.
Published: April 2023

PDF file - 400K
Figure S1a from Validation of Intratumoral T-bet+ Lymphoid Cells as Predictors of Disease-Free Survival in Breast Cancer
Authors: Mulligan Anna Marie , Pinnaduwage Dushanthi , Tchatchou Sandrine , Bull Shelley B. , Andrulis Irene L.
Published: April 2023

This figure compares K-M curves of DFS by di- and tri- categorizations of T-bet for several (10, 15, 20, 25,) cut points. It is evident in the three-level KM plots that the absent and low count groups of T-bet are indistinguishable for the cut-points used to define the high versus the low count group of T-bet.
Supplementary Figure 2 from In Vitro Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and In Vivo Toxicology in Non-Human Primates
Authors: Wang Changyu , Thudium Kent B. , Han Minhua , Wang Xi-Tao , Huang Haichun , Feingersh Diane , Garcia Candy , Wu Yi , Kuhne Michelle , Srinivasan Mohan , Singh Sujata , Wong Susan , Garner Neysa , Leblanc Heidi , Bunch R. Todd , Blanset Diann , Selby Mark J. , Korman Alan J.
Published: April 2023

PDF file - 376K, Figure S2. Epitope of nivolumab on human PD-1.
Supplementary Tables S1-S3 from A Paracrine Role for IL6 in Prostate Cancer Patients: Lack of Production by Primary or Metastatic Tumor Cells
Authors: Yu Shu-Han , Zheng Qizhi , Esopi David , Macgregor-Das Anne , Luo Jun , Antonarakis Emmanuel S. , Drake Charles G. , Vessella Robert , Morrissey Colm , De Marzo Angelo M. , Sfanos Karen S.
Published: April 2023

Supplementary Table S1. Clinical Characteristics of Patient Samples Used in the Study. Supplementary Table S2. Results of Oncomine Database Query for IL-6 Expression. Supplementary Table S3. Assessment of Levels and Distribution of IL-6 mRNA Expression in Metastatic Tissue.
Supplementary Figure S3 from A Paracrine Role for IL6 in Prostate Cancer Patients: Lack of Production by Primary or Metastatic Tumor Cells
Authors: Yu Shu-Han , Zheng Qizhi , Esopi David , Macgregor-Das Anne , Luo Jun , Antonarakis Emmanuel S. , Drake Charles G. , Vessella Robert , Morrissey Colm , De Marzo Angelo M. , Sfanos Karen S.
Published: April 2023

Western blot on NCI-H460 cells. Western blot on protein lysates from NCI-H460 cells grown without (1) or with (2) protein transport inhibition with monensin (Golgi-Stop{trade mark, serif}). (3) 300 ng recombinant IL-6, positive control.
Supplementary Methods from Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy
Authors: Wu Xinqi , Giobbie-Hurder Anita , Liao Xiaoyun , Connelly Courtney , Connolly Erin M. , Li Jingjing , Manos Michael P. , Lawrence Donald , McDermott David , Severgnini Mariano , Zhou Jun , Gjini Evisa , Lako Ana , Lipschitz Mikel , Pak Christine J. , Abdelrahman Sara , Rodig Scott , Hodi F. Stephen
Published: April 2023

Culture and treatment of endothelial cells and melanoma cells. Generation and polarization of monocyte derived macrophages (MDM). Purification of ANGPT2 antibodies from plasma. Immunoblot analyses.
Supplementary Figures 1 - 18, Table 1 from Melanoma-Derived Wnt5a Promotes Local Dendritic-Cell Expression of IDO and Immunotolerance: Opportunities for Pharmacologic Enhancement of Immunotherapy
Authors: Holtzhausen Alisha , Zhao Fei , Evans Kathy S. , Tsutsui Masahito , Orabona Ciriana , Tyler Douglas S. , Hanks Brent A.
Published: April 2023

Supplementary Figure 1. Human melanoma upregulates expression of several Wnt ligands. Supplementary Figure 2. B16 melanoma conditioned media stimulates paracrine activation of the β-catenin signaling pathway. Supplementary Figure 3. Both the BRAFV600EPTEN-/- transgenic melanoma model and the B16 melanoma cell line express relatively high levels of the Wnt5a ligand. Supplementary Figure 4. Isolation of tumor-infiltrating and tumor-draining lymph node dendritic cells from the BRAFV600EPTEN-/- transgenic melanoma model. Supplementary Figure 5. Characterization of the BRAFV600EPTEN-/- transgenic melanoma-derived cell line. Supplementary Figure 6. Tumor-draining lymph node and distant lymph node dendritic cell β-catenin signaling activity in the TCF/Lef1-EGFP reporter mouse model. Supplementary Figure 7. Characterization of the BRAFV600EPTEN-/- transgenic melanoma-derived cell line genetically silenced for Wnt5a expression. Supplementary Figure 8. Representative flow cytometry data for the in vitro regulatory T cell differentiation assay. Supplementary Figure 9. Wnt-induced alterations of bone marrow-derived dendritic cell surface phenotype, cytokine expression, and effector T cell activation capacity. Supplementary Figure 10. Supportive data for IDO enzymatic studies and for Wnt-β-catenin signaling studies in dendritic cells. Supplementary Figure 11. Differential effects of Wnt3a versus Wnt5a on dendritic cell β-catenin signaling and IDO expression. Supplementary Figure 12. Analysis of IFN-γ-dependence of Wnt5a- and Wnt3a-induced IDO expression in dendritic cells. Supplementary Figure 13. Representative flow cytometry data of lymph node regulatory T cell populations in FoxP3-mRFP transgenic mice. Supplementary Figure 14. Development of a PCR-based BRAFV600EPTEN-/- melanoma lymph node metastasis detection assay. Supplementary Figure 15. Characterization of the B16 melanoma cell line genetically silenced for the Porcn acyl transferase enzyme. Supplementary Figure 16. Porcn inhibition suppresses Wnt ligand secretion by the B16 and BRAFV600EPTEN-/- melanoma cell lines. Supplementary Figure 17. Supportive data for Porcn inhibition in the in vivo B16 melanoma model. Supplementary Figure 18. Supportive data for human sentinel lymph node dendritic cell β-catenin signaling pathway analysis. Supplementary Table 1. Primer sequences utilized in the current study.
Supplementary Figure Legends from Neutrophils Increase Oral Squamous Cell Carcinoma Invasion through an Invadopodia-Dependent Pathway
Authors: Glogauer Judah E. , Sun Chun X. , Bradley Grace , Magalhaes Marco A.O.
Published: April 2023

Supplementary Figure Legends
Supplementary Figure 5 from STING Ligand c-di-GMP Improves Cancer Vaccination against Metastatic Breast Cancer
Authors: Chandra Dinesh , Quispe-Tintaya Wilber , Jahangir Arthee , Asafu-Adjei Denise , Ramos Ilyssa , Sintim Herman O. , Zhou Jie , Hayakawa Yoshihiro , Karaolis David K.R. , Gravekamp Claudia
Published: April 2023

PDF file - 164K, Figure S5: Developing of a therapeutic protocol with c-di-GMP and Listeria for clinical application.
Supplemental Methods from Enhanced Tumor Control with Combination mTOR and PD-L1 Inhibition in Syngeneic Oral Cavity Cancers
Authors: Moore Ellen C. , Cash Harrison A. , Caruso Andria M. , Uppaluri Ravindra , Hodge James W. , Van Waes Carter , Allen Clint T.
Published: April 2023

This file contains detailed methods for both our in vivo animal and flow cytometry experiments. This includes drug doses and scheduling, an inventory of antibodies, and appropriate supporting references.
Supplemental Figure 3 from Mast Cells Boost Myeloid-Derived Suppressor Cell Activity and Contribute to the Development of Tumor-Favoring Microenvironment
Authors: Danelli Luca , Frossi Barbara , Gri Giorgia , Mion Francesca , Guarnotta Carla , Bongiovanni Lucia , Tripodo Claudio , Mariuzzi Laura , Marzinotto Stefania , Rigoni Alice , Blank Ulrich , Colombo Mario P. , Pucillo Carlo E.
Published: April 2023

Role of CD40:CD40L and cell-to-cell contact in the activation of M-MDSC:MC suppressive axis.
Supplemental Figure 1 from Mast Cells Boost Myeloid-Derived Suppressor Cell Activity and Contribute to the Development of Tumor-Favoring Microenvironment
Authors: Danelli Luca , Frossi Barbara , Gri Giorgia , Mion Francesca , Guarnotta Carla , Bongiovanni Lucia , Tripodo Claudio , Mariuzzi Laura , Marzinotto Stefania , Rigoni Alice , Blank Ulrich , Colombo Mario P. , Pucillo Carlo E.
Published: April 2023

MDSC accumulation in CT-26 tumor bearing mice and migration in response to mast cells and to conditioned media from colon cancer cell line.
Supplemental Figure S2 from Extracellular Vesicles Present in Human Ovarian Tumor Microenvironments Induce a Phosphatidylserine-Dependent Arrest in the T-cell Signaling Cascade
Authors: Kelleher Raymond J. , Balu-Iyer Sathy , Loyall Jenni , Sacca Anthony J. , Shenoy Gautam N. , Peng Peng , Iyer Vandana , Fathallah Anas M. , Berenson Charles S. , Wallace Paul K. , Tario Joseph , Odunsi Kunle , Bankert Richard B.
Published: April 2023

Fig S2. PS/PC liposome titration.
Supplementary Figure Legends from Combination of 4-1BB Agonist and PD-1 Antagonist Promotes Antitumor Effector/Memory CD8 T Cells in a Poorly Immunogenic Tumor Model
Authors: Chen Shihao , Lee Li-Fen , Fisher Timothy S. , Jessen Bart , Elliott Mark , Evering Winston , Logronio Kathryn , Tu Guang Huan , Tsaparikos Konstantinos , Li Xiaoai , Wang Hui , Ying Chi , Xiong Mengli , VanArsdale Todd , Lin John C.
Published: April 2023

Supplementary Figure Legends
Supplemental Figure 1 from Inhibition of Fatty Acid Oxidation Modulates Immunosuppressive Functions of Myeloid-Derived Suppressor Cells and Enhances Cancer Therapies
Authors: Hossain Fokhrul , Al-Khami Amir A. , Wyczechowska Dorota , Hernandez Claudia , Zheng Liqin , Reiss Krzystoff , Valle Luis Del , Trillo-Tinoco Jimena , Maj Tomasz , Zou Weiping , Rodriguez Paulo C. , Ochoa Augusto C.
Published: April 2023

Supplemental Figure 1: FAO is increased in immunosuppressive T-MDSCs.
Supplemenatl Figure 6 from Inhibition of Fatty Acid Oxidation Modulates Immunosuppressive Functions of Myeloid-Derived Suppressor Cells and Enhances Cancer Therapies
Authors: Hossain Fokhrul , Al-Khami Amir A. , Wyczechowska Dorota , Hernandez Claudia , Zheng Liqin , Reiss Krzystoff , Valle Luis Del , Trillo-Tinoco Jimena , Maj Tomasz , Zou Weiping , Rodriguez Paulo C. , Ochoa Augusto C.
Published: April 2023

Supplemental Figure 6. The combined use of Etomoxir and CTX in vivo inhibits all immunosuppressive activity in T-MDSCs.
Supplementary Table 2 from Intralesional Treatment of Stage III Metastatic Melanoma Patients with L19–IL2 Results in Sustained Clinical and Systemic Immunologic Responses
Authors: Weide Benjamin , Eigentler Thomas K. , Pflugfelder Annette , Zelba Henning , Martens Alexander , Pawelec Graham , Giovannoni Leonardo , Ruffini Pier Adelchi , Elia Giuliano , Neri Dario , Gutzmer Ralf , Becker Jürgen C. , Garbe Claus
Published: April 2023

XLSX file - 82K, Change in frequency of cytokine-releasing T cells at different time points.
Supplementary Table 1 from Intralesional Treatment of Stage III Metastatic Melanoma Patients with L19–IL2 Results in Sustained Clinical and Systemic Immunologic Responses
Authors: Weide Benjamin , Eigentler Thomas K. , Pflugfelder Annette , Zelba Henning , Martens Alexander , Pawelec Graham , Giovannoni Leonardo , Ruffini Pier Adelchi , Elia Giuliano , Neri Dario , Gutzmer Ralf , Becker Jürgen C. , Garbe Claus
Published: April 2023

PDF file - 119K, List of lesions present at screening and overall patient responses (modified irRC and RECIST).
Supplementary Figure Legend from Ablation of B7-H3 but Not B7-H4 Results in Highly Increased Tumor Burden in a Murine Model of Spontaneous Prostate Cancer
Authors: Kreymborg Katharina , Haak Stefan , Murali Rajmohan , Wei Joyce , Waitz Rebecca , Gasteiger Georg , Savage Peter A. , van den Brink Marcel R. M. , Allison James P.
Published: April 2023

Supplementary Figure Legend
Supplementary Figures 1 through 3 from Immune-Derived PD-L1 Gene Expression Defines a Subgroup of Stage II/III Colorectal Cancer Patients with Favorable Prognosis Who May Be Harmed by Adjuvant Chemotherapy
Authors: Dunne Philip D. , McArt Darragh G. , O'Reilly Paul G. , Coleman Helen G. , Allen Wendy L. , Loughrey Maurice , Van Schaeybroeck Sandra , McDade Simon , Salto-Tellez Manuel , Longley Daniel B. , Lawler Mark , Johnston Patrick G.
Published: April 2023

Supplementary figure 1: A +B. Hierarchical clustering of microdissected stromal and epithelial (A) and FACS sorted endothelial, fibroblast, epithelial and leukocyte (B) cell populations using previously published non-epithelial derived gene list confirms purity of cell populations. C and D. PCA plot of data presented in top panels highlights clear stratification of samples based on cell lineage using this gene signature. E. Expression values for IFNG expression according to cell-of-origin confirms immune-derived nature of signal. Supplementary figure 2: Association of high PD-L1 expression with MSI subtype and high immune infiltrate. Supplementary figure 3: A. Dot and boxplots of PD-L1 mean gene expression values stratified by MSI status highlights significant association between PD-L1 transcription levels and MSI genotype. B. (Left) Hierarchical clustering of stage II/III CRC cohort based on expression profiles of CD274, CTLA4, LAG3 and IDO1. (Right) Significant upregulation of CD274, IDO1, CTLA4 and LAG3 genes in the PD-L1high subgroup. C. (Left) Dot plot and boxplot of IFNG expression levels stratified by PD-L1-subgroup. (Right) Significant upregulation of IFNG gene in the PD-L1high subgroup.
Supplementary Figure 2 from Intralesional Treatment of Stage III Metastatic Melanoma Patients with L19–IL2 Results in Sustained Clinical and Systemic Immunologic Responses
Authors: Weide Benjamin , Eigentler Thomas K. , Pflugfelder Annette , Zelba Henning , Martens Alexander , Pawelec Graham , Giovannoni Leonardo , Ruffini Pier Adelchi , Elia Giuliano , Neri Dario , Gutzmer Ralf , Becker Jürgen C. , Garbe Claus
Published: April 2023

PDF file - 870K, Detailed gating strategy of all the analyzed immune cell subsets.
Supplementary Figure 1 from Intralesional Treatment of Stage III Metastatic Melanoma Patients with L19–IL2 Results in Sustained Clinical and Systemic Immunologic Responses
Authors: Weide Benjamin , Eigentler Thomas K. , Pflugfelder Annette , Zelba Henning , Martens Alexander , Pawelec Graham , Giovannoni Leonardo , Ruffini Pier Adelchi , Elia Giuliano , Neri Dario , Gutzmer Ralf , Becker Jürgen C. , Garbe Claus
Published: April 2023

PDF file - 945K, Frequency and severity of common adverse events.
Supplemental Figure 3 from CALGB 150905 (Alliance): Rituximab Broadens the Antilymphoma Response by Activating Unlicensed NK Cells
Authors: Du Juan , Lopez-Verges Sandra , Pitcher Brandelyn N. , Johnson Jeffrey , Jung Sin-Ho , Zhou Lili , Hsu Katharine , Czuczman Myron S. , Cheson Bruce , Kaplan Lawrence , Lanier Lewis L. , Venstrom Jeffrey M.
Published: April 2023

Rituximab increases cytotoxicity mediated by unlicensed NK cells.
Supplementary Fig. S9 from Salmonella-Based Therapy Targeting Indoleamine 2,3-Dioxygenase Coupled with Enzymatic Depletion of Tumor Hyaluronan Induces Complete Regression of Aggressive Pancreatic Tumors
Authors: Manuel Edwin R. , Chen Jeremy , D'Apuzzo Massimo , Lampa Melanie G. , Kaltcheva Teodora I. , Thompson Curtis B. , Ludwig Thomas , Chung Vincent , Diamond Don J.
Published: April 2023

Evaluation of inflammatory cytokines and ICAM-1 in tumors of mice treated with PEGPH20/shIDO-ST. Mice bearing 14 day orthotopic KPC tumors were treated with indicated regimens. Tumors were excised 96 hours post-treatment and used for RT-qPCR to detect cytokines or immunofluorescence to detect ICAM-1. Data are representative of multiple experiments. (A) Total mRNA was isolated (Qiagen) to generate cDNA libraries using a RevertAid First Strand DNA kit (Thermo Scientific) and analyzed for indicated cytokine mRNAs (Power Syber Green kit, 7300 RT-PCR cycler (Applied Biosystems)). Experimental Ct values were normalized to GAPDH. Relative expression levels were calculated using the equation 2-delta deltaCt and using the CT values of the PEGPH20 only treatment group as the comparator . *p{less than or equal to}0.05, **p{less than or equal to}0.01, ***p{less than or equal to}0.001 using 1-way ANOVA. (B) Tissue sections from indicated treatment groups were stained for ICAM-1 (green), PMN (red) and nuclei (DAPI, blue). Arrows represent leading edges of PMN infiltration associated with ICAM-1. Magnification, 10X.
Supplementary Figure 2 from Optimization of Peptide Vaccines to Induce Robust Antitumor CD4 T-cell Responses
Authors: Kumai Takumi , Lee Sujin , Cho Hyun-Il , Sultan Hussein , Kobayashi Hiroya , Harabuchi Yasuaki , Celis Esteban
Published: April 2023

MHC Class II expression on B16F10 melanoma cells
Supplementary Figure 1 from Optimization of Peptide Vaccines to Induce Robust Antitumor CD4 T-cell Responses
Authors: Kumai Takumi , Lee Sujin , Cho Hyun-Il , Sultan Hussein , Kobayashi Hiroya , Harabuchi Yasuaki , Celis Esteban
Published: April 2023

TriVax with or without OX40 agonist is superior to a conventional adjuvant in inducing CD4 T cell responses
Supplementary Fig. S6 from Salmonella-Based Therapy Targeting Indoleamine 2,3-Dioxygenase Coupled with Enzymatic Depletion of Tumor Hyaluronan Induces Complete Regression of Aggressive Pancreatic Tumors
Authors: Manuel Edwin R. , Chen Jeremy , D'Apuzzo Massimo , Lampa Melanie G. , Kaltcheva Teodora I. , Thompson Curtis B. , Ludwig Thomas , Chung Vincent , Diamond Don J.
Published: April 2023

Ex-vivo depletion of HA from KPC tumor sections with hyaluronidase and PEGPH20. To confirm specificity of HA staining, 14-day orthotopic KPC tumors were extracted, flash frozen in OCT medium, sectioned, and fixed onto Colorfrost slides (Fisher Scientific) with acid formalin. Sections were then incubated with 1 mg/ml bovine testis hyaluronidase (Sigma) , PEGPH20, or left untreated for 1 hour in a humidified 37degreeC incubator. Sections were then incubated with biotinylated HA binding protein (HABP, 5ug/ml) overnight at 4degreeC followed by treatment using an avidin-biotin peroxidase kit (ABC kit, Vectastain). Magnification:10X.
Supplemental Table 3 from Identification of Anti-CA125 Antibody Responses in Ovarian Cancer Patients by a Novel Deep Sequence–Coupled Biopanning Platform
Authors: Frietze Kathryn M. , Roden Richard B.S. , Lee Ji-Hyun , Shi Yang , Peabody David S. , Chackerian Bryce
Published: April 2023

Supplemental Table 3. Demographics and clinical characteristics of the study patients (n=100).
Supplemental Table 1 from Identification of Anti-CA125 Antibody Responses in Ovarian Cancer Patients by a Novel Deep Sequence–Coupled Biopanning Platform
Authors: Frietze Kathryn M. , Roden Richard B.S. , Lee Ji-Hyun , Shi Yang , Peabody David S. , Chackerian Bryce
Published: April 2023

Supplemental Table 1. Top 25 ranked peptides from Round 2 of selection with OvCa patient IgG.
Supplementary Fig. S13 from Salmonella-Based Therapy Targeting Indoleamine 2,3-Dioxygenase Coupled with Enzymatic Depletion of Tumor Hyaluronan Induces Complete Regression of Aggressive Pancreatic Tumors
Authors: Manuel Edwin R. , Chen Jeremy , D'Apuzzo Massimo , Lampa Melanie G. , Kaltcheva Teodora I. , Thompson Curtis B. , Ludwig Thomas , Chung Vincent , Diamond Don J.
Published: April 2023

Isolation and characterization of splenic PMN from PEGPH20/ shIDO-ST treated mice. (A) PMN were purified from crude spleen homogenates of treated mice through negative bead selection. Percentage of PMN in crude and purified preparations were determined by flow cytometry. (B) PEGPH20/shIDO-ST treatment was administered to mice that were depleted of PMN using Gr-1 antibody or administered IgG control. KPC-luc tumor growth was monitored by IVIS at indicated time points and quantitated using Living ImageÂ® software.
Supplementary Figure S3 from Human Leukocyte Antigen (HLA) A*1101-Restricted Epstein-Barr Virus–Specific T-cell Receptor Gene Transfer to Target Nasopharyngeal Carcinoma
Authors: Zheng Yong , Parsonage Greg , Zhuang Xiaodong , Machado Lee R. , James Christine H. , Salman Asmaa , Searle Peter F. , Hui Edwin P. , Chan Anthony T.C. , Lee Steven P.
Published: April 2023

Nucleotide sequence encoding coTCRcys.
Supplementary Fig. S12 from Salmonella-Based Therapy Targeting Indoleamine 2,3-Dioxygenase Coupled with Enzymatic Depletion of Tumor Hyaluronan Induces Complete Regression of Aggressive Pancreatic Tumors
Authors: Manuel Edwin R. , Chen Jeremy , D'Apuzzo Massimo , Lampa Melanie G. , Kaltcheva Teodora I. , Thompson Curtis B. , Ludwig Thomas , Chung Vincent , Diamond Don J.
Published: April 2023

Western blot analysis of cleaved caspase 3 (CC3). Mice bearing 14 day orthotopic KPC tumors were treated with indicated regimens. Tumors were excised 96 hours post-treatment, homogenized, and total protein was extracted using cell lysis buffer containing a protease inhibitor cocktail mix (Roche). Equal amounts of protein (Bradford) were loaded. Blots were stained separately for pro-caspase 3 and CC3. Equal loading of samples was confirmed by stripping CC3 membranes and reprobing for Î²-actin. Data are representative of multiple experiments.
Supplementary Fig. S11 from Salmonella-Based Therapy Targeting Indoleamine 2,3-Dioxygenase Coupled with Enzymatic Depletion of Tumor Hyaluronan Induces Complete Regression of Aggressive Pancreatic Tumors
Authors: Manuel Edwin R. , Chen Jeremy , D'Apuzzo Massimo , Lampa Melanie G. , Kaltcheva Teodora I. , Thompson Curtis B. , Ludwig Thomas , Chung Vincent , Diamond Don J.
Published: April 2023

Evaluation of ST and PMN in PEGPH20 treated tumors at 24hr and 48hr time points. To determine the distribution of ST and PMN early during treatment, mice with 14 day orthotopic tumors were treated with indicated regimens. Tumors were excised at (A) 24h or (B) 48h, flash frozen in OCT, sectioned, and fixed onto Colorfrost slides (Fisher Scientific) using cold acetone. Slides were then costained with antibodies specific for ST and PMN. Slides were counterstained with appropriate fluorescently labeled secondary antibody and DAPI. Magnification: 20X
Supplementary Figure S1 from Human Leukocyte Antigen (HLA) A*1101-Restricted Epstein-Barr Virus–Specific T-cell Receptor Gene Transfer to Target Nasopharyngeal Carcinoma
Authors: Zheng Yong , Parsonage Greg , Zhuang Xiaodong , Machado Lee R. , James Christine H. , Salman Asmaa , Searle Peter F. , Hui Edwin P. , Chan Anthony T.C. , Lee Steven P.
Published: April 2023

Minimal mispairing with the exogenous TCR b chain shown using Mock- and WT TCR-transduced T-cells from an NPC patient.
Supplementary Figure Legends from PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer
Authors: Wimberly Hallie , Brown Jason R. , Schalper Kurt , Haack Herbert , Silver Matthew R. , Nixon Christian , Bossuyt Veerle , Pusztai Lajos , Lannin Donald R. , Rimm David L.
Published: April 2023

Supplementary Figure Legends
Supplemental Table 1 from PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer
Authors: Wimberly Hallie , Brown Jason R. , Schalper Kurt , Haack Herbert , Silver Matthew R. , Nixon Christian , Bossuyt Veerle , Pusztai Lajos , Lannin Donald R. , Rimm David L.
Published: April 2023

Supplemental Table 1. Exclusion of Ki67 from Table 4 shows that both stromal and epithelial PD-L1 expressions are highly significant in multivariate analysis.
Supplementary Figure 2 from Inhibition of CD39 Enzymatic Function at the Surface of Tumor Cells Alleviates Their Immunosuppressive Activity
Authors: Bastid Jeremy , Regairaz Anne , Bonnefoy Nathalie , Déjou Cécile , Giustiniani Jérôme , Laheurte Caroline , Cochaud Stéphanie , Laprevotte Emilie , Funck-Brentano Elisa , Hemon Patrice , Gros Laurent , Bec Nicole , Larroque Christian , Alberici Gilles , Bensussan Armand , Eliaou Jean-François
Published: April 2023

Representative IHC staining of CD39 expression in vascular endothelial cells and lymphocytes from various normal tissues (clone 22A9).
Supplementary Figure 1 from Inhibition of CD39 Enzymatic Function at the Surface of Tumor Cells Alleviates Their Immunosuppressive Activity
Authors: Bastid Jeremy , Regairaz Anne , Bonnefoy Nathalie , Déjou Cécile , Giustiniani Jérôme , Laheurte Caroline , Cochaud Stéphanie , Laprevotte Emilie , Funck-Brentano Elisa , Hemon Patrice , Gros Laurent , Bec Nicole , Larroque Christian , Alberici Gilles , Bensussan Armand , Eliaou Jean-François
Published: April 2023

Validation of CD39 IHC.
Supplementary Table 1 from Reprogramming Tumor-Infiltrating Dendritic Cells for CD103+CD8+ Mucosal T-cell Differentiation and Breast Cancer Rejection
Authors: Wu Te-Chia , Xu Kangling , Banchereau Romain , Marches Florentina , Yu Chun I. , Martinek Jan , Anguiano Esperanza , Pedroza-Gonzalez Alexander , Snipes G. Jackson , O'Shaughnessy Joyce , Nishimura Stephen , Liu Yong-Jun , Pascual Virginia , Banchereau Jacques , Oh Sangkon , Palucka Karolina
Published: April 2023

PDF file - 37K, Supplementary Table 1. Primary breast tumor samples were received from Baylor University Medical Center.
Supplementary Figure 2 from Efficient Induction of Antitumor Immunity by Synthetic Toll-like Receptor Ligand–Peptide Conjugates
Authors: Zom Gijs G. , Khan Selina , Britten Cedrik M. , Sommandas Vinod , Camps Marcel G.M. , Loof Nikki M. , Budden Christina F. , Meeuwenoord Nico J. , Filippov Dmitri V. , van der Marel Gijsbert A. , Overkleeft Hermen S. , Melief Cornelis J.M. , Ossendorp Ferry
Published: April 2023

PDF file - 679K, Supplementary figure 2. In vitro T-cell activation induced by conjugated SLP.
Supplementary Figure S5 from Immunogenic Subtypes of Breast Cancer Delineated by Gene Classifiers of Immune Responsiveness
Authors: Miller Lance D. , Chou Jeff A. , Black Michael A. , Print Cristin , Chifman Julia , Alistar Angela , Putti Thomas , Zhou Xiaobo , Bedognetti Davide , Hendrickx Wouter , Pullikuth Ashok , Rennhack Jonathan , Andrechek Eran R. , Demaria Sandra , Wang Ena , Marincola Francesco M.
Published: April 2023

IPA network schematics of regulatory pathways identified by IBE-IBD differentially expressed genes.
Supplementary Figure 1 from Efficient Induction of Antitumor Immunity by Synthetic Toll-like Receptor Ligand–Peptide Conjugates
Authors: Zom Gijs G. , Khan Selina , Britten Cedrik M. , Sommandas Vinod , Camps Marcel G.M. , Loof Nikki M. , Budden Christina F. , Meeuwenoord Nico J. , Filippov Dmitri V. , van der Marel Gijsbert A. , Overkleeft Hermen S. , Melief Cornelis J.M. , Ossendorp Ferry
Published: April 2023

PDF file - 266K, Supplementary figure 1. DC maturation by TLR2-L SLP conjugates.
Supplemental Figure Legend from αβ TCR-Mediated Recognition: Relevance to Tumor-Antigen Discovery and Cancer Immunotherapy
Authors: Reinherz Ellis L.
Published: April 2023

Supplemental Figure Legend
Supplementary Figure Legends from Episomal Expression of Truncated Listeriolysin O in LmddA-LLO–E7 Vaccine Enhances Antitumor Efficacy by Preferentially Inducing Expansions of CD4+FoxP3− and CD8+ T Cells
Authors: Chen Zhisong , Ozbun Laurent , Chong Namju , Wallecha Anu , Berzofsky Jay A. , Khleif Samir N.
Published: April 2023

PDF file - 77K
Supplementary figures S1-S7 and Supplementary tables S1-S2 from Dasatinib Changes Immune Cell Profiles Concomitant with Reduced Tumor Growth in Several Murine Solid Tumor Models
Authors: Hekim Can , Ilander Mette , Yan Jun , Michaud Erin , Smykla Richard , Vähä-Koskela Markus , Savola Paula , Tähtinen Siri , Saikko Leena , Hemminki Akseli , Kovanen Panu E. , Porkka Kimmo , Lee Francis Y.F. , Mustjoki Satu
Published: April 2023

Supplementary Figure S1. Dasatinib-induced rapid lymphocyte mobilization and tumor growth rate correlation Supplementary Figure S2. Immunohistochemical staining of CD8+ T cells in the tumor tissues of A) vehicle treated control group and B) dasatinib treated group Supplementary Figure 3. Confirmation of CD4+, CD8+ T cells and NK cell depletion by FACS Supplementary Figure 4. Immunophenotypic analysis of B16.OVA tumor infiltrating leukocytes Supplementary Figure 5. Immunophenotypic analysis of 1956 tumor infiltrating leukocytes Supplementary Figure 6. Immunophenotypic analysis of MC38 tumor infiltrating leukocytes Supplementary Figure 7. Immunophenotypic analysis of 4T1 tumor infiltrating leukocytes Supplementary Table S1. A summary of anti-mouse antibodies used for CyTOF mass cytometry analysis Supplementary Table S2. Frequencies of intratumoral T cell subsets analysed by CyTOF.
Supplementary Tables 1 and 2 and Supplementary Figures 1 through 7 from Efficient Eradication of Established Tumors in Mice with Cationic Liposome-Based Synthetic Long-Peptide Vaccines
Authors: Varypataki Eleni Maria , Benne Naomi , Bouwstra Joke , Jiskoot Wim , Ossendorp Ferry
Published: April 2023

Supplementary Table 1: Loading efficiencies of OVA24 and OVA17 in liposomes Supplementary fig.1: Loading of OVA17 and OVA24 in liposomes as function of adjustable initial peptide concentration Supplementary Table 2:Physicochemical properties of liposomes Supplementary fig.2:In vitro DC activation (A) and subsequent CD8+ T cell activation (B) Supplementary fig.3: Gating strategy for detection of OVA-specific CD8+ T cells Supplementary fig.4: Intracellular cytokine analysis of OVA SLPs- immunised mice Supplementary fig.5: Detection of ag-specific T-cells in blood upon vaccination with Pam- and CpG- adjuvanted liposomes (A) and in vivo cytotoxicity (B) Supplementary fig.6: Gating strategy for detection of HPV E7-specific CD8+ T cells Supplementary fig.7: Tumor outgrowth and survival plots of mice vaccinated with HPV E7-formulations
Supplementary Materials and Methods from Analyses of Pretherapy Peripheral Immunoscore and Response to Vaccine Therapy
Authors: Farsaci Benedetto , Donahue Renee N. , Grenga Italia , Lepone Lauren M. , Kim Peter S. , Dempsey Brendan , Siebert Janet C. , Ibrahim Nuhad K. , Madan Ravi A. , Heery Christopher R. , Gulley James L. , Schlom Jeffrey
Published: April 2023

Custom software for the calculation of the peripheral immunoscore.
Supplementary Figures 1 through 3 and Supplementary Tables 1 through 3 from Analyses of Pretherapy Peripheral Immunoscore and Response to Vaccine Therapy
Authors: Farsaci Benedetto , Donahue Renee N. , Grenga Italia , Lepone Lauren M. , Kim Peter S. , Dempsey Brendan , Siebert Janet C. , Ibrahim Nuhad K. , Madan Ravi A. , Heery Christopher R. , Gulley James L. , Schlom Jeffrey
Published: April 2023

Supplementary Figure S1: Gating strategy to identify classic peripheral immune cell types and refined immune cell subsets with phenotypes reflecting immune function that were used to generate the peripheral immunoscores of patients treated with docetaxel plus or minus PANVAC. Supplementary Figure S2: Gating strategy to identify classic peripheral immune cell types and refined immune cell subsets with phenotypes reflecting immune function that were used to generate the peripheral immunoscores of patients treated with Quadramet plus or minus PROSTVAC. Supplementary Figure S3: Point assignment method used in generating peripheral immunoscores. Supplementary Table S1: Antibodies and panels used in flow cytometry analysis to identify immune cells. Supplementary Table S2: PBMC frequencies (min, median, max) and bin cutoffs used in generating peripheral immunoscores in breast cancer patients treated with docetaxel +/- PANVAC vaccine and prostate cancer patients treated with Sm-153 (Quadramet) +/- PROSTVAC vaccine. Supplementary Table S3: Summation of points assigned to individual subsets to generate peripheral immunoscore.
Supplementary Figure 3 from Intravesical BCG Induces CD4+ T-Cell Expansion in an Immune Competent Model of Bladder Cancer
Authors: Kates Max , Nirschl Thomas , Sopko Nikolai A. , Matsui Hotaka , Kochel Christina M. , Reis Leonardo O. , Netto George J. , Hoque Mohammad O. , Hahn Noah M. , McConkey David J. , Baras Alex S. , Drake Charles G. , Bivalacqua Trinity J.
Published: April 2023

5 BCG treated rats, 5 untreated rats, and 20 controls rat were sacrificed and bladders were processed in single cell suspensions. CD4 and CD8 T cells were isolated for each sample and RNA was extracted. A gene expression analysis was subsequently performed on sorted CD4 and CD8 cells from each group using an Affymetrix Rat Gene 1.0 ST Array. MVA plot of sorted (A) CD8 and (B) CD4 T cells from MNU rats treated with BCG vs Untreated tumors. Genes selected from the Gene Ontology term "Immune Response" that have <2SD fold change are highlighted in red were overexpressed with BCG and blue where underexpressed with BCG. (C) Q/Q plot depicting relative fold change after BCG (vs untreated tumor) of genes on sorted CD4 vs CD8 cells.
Supplemental Figure S2 from CARD9 Promotes Sex-Biased Colon Tumors in the APCmin Mouse Model
Authors: Leo Vonny I. , Tan Sze Huey , Bergmann Hanna , Cheah Peh Yean , Chew Min Hoe , Lim Kiat Hon , Ruland Jürgen , Reilly Patrick T.
Published: April 2023

Supplemental Figure S2. Additional cytokine analyses.
Supplementary Figure 2 from Intravesical BCG Induces CD4+ T-Cell Expansion in an Immune Competent Model of Bladder Cancer
Authors: Kates Max , Nirschl Thomas , Sopko Nikolai A. , Matsui Hotaka , Kochel Christina M. , Reis Leonardo O. , Netto George J. , Hoque Mohammad O. , Hahn Noah M. , McConkey David J. , Baras Alex S. , Drake Charles G. , Bivalacqua Trinity J.
Published: April 2023

(A) Rats 8 weeks post MNU were treated intravesically with MMC, MMC+BCG, and Cisplatin for 6 weeks (n=5 for each group). Bladders were harvested at week 16 and then digested into single cell suspensions and T cell populations analyzed with flow cytometry. (B) Flow Cytometry was then performed on digested bladders, and T cell subpopulations are reported as percentages, cell numbers, and (C) ratios. A "*" denotes statistical significance. All experiments were performed 2 times.
Supplementary Figure 1 from IFNγ-Dependent Interactions between ICAM-1 and LFA-1 Counteract Prostaglandin E2–Mediated Inhibition of Antitumor CTL Responses
Authors: Basingab Fatemah Salem , Ahmadi Maryam , Morgan David John
Published: April 2023

ICAM-1-LFA-1 interactions reverse the effect of PGE2 on CL4 CD8+ T cell proliferation.
Supplementary Video 4 from Estradiol Promotes Breast Cancer Cell Migration via Recruitment and Activation of Neutrophils
Authors: Vazquez Rodriguez Gabriela , Abrahamsson Annelie , Jensen Lasse Dahl Ejby , Dabrosin Charlotta
Published: April 2023

Video showing how breast cancer cells invasion and movement is impaired due to blocking LFA-1.
Supplementary Video 1 from Estradiol Promotes Breast Cancer Cell Migration via Recruitment and Activation of Neutrophils
Authors: Vazquez Rodriguez Gabriela , Abrahamsson Annelie , Jensen Lasse Dahl Ejby , Dabrosin Charlotta
Published: April 2023

Video showing how eutrophils aid the intravasation and invasion of breast cancer cells
Supplementary Materials, Supplementary Figure Legends, and Supplementary Table 1 from Estradiol Promotes Breast Cancer Cell Migration via Recruitment and Activation of Neutrophils
Authors: Vazquez Rodriguez Gabriela , Abrahamsson Annelie , Jensen Lasse Dahl Ejby , Dabrosin Charlotta
Published: April 2023

Supplementary materials and figure legends. Supplementary Table 1: Characteristics of breast cancers subjected to microdialysis.
Supplementary Figure 1 from Estradiol Promotes Breast Cancer Cell Migration via Recruitment and Activation of Neutrophils
Authors: Vazquez Rodriguez Gabriela , Abrahamsson Annelie , Jensen Lasse Dahl Ejby , Dabrosin Charlotta
Published: April 2023

Validation of neutrophil marker and morphology
Supplementary Figure S5 from Safety of Targeting ROR1 in Primates with Chimeric Antigen Receptor–Modified T Cells
Authors: Berger Carolina , Sommermeyer Daniel , Hudecek Michael , Berger Michael , Balakrishnan Ashwini , Paszkiewicz Paulina J. , Kosasih Paula L. , Rader Christoph , Riddell Stanley R.
Published: April 2023

R12-ROR1 CAR-T cells recognize ROR1+ T-APC in vitro.
Supplementary Figure S1 from Safety of Targeting ROR1 in Primates with Chimeric Antigen Receptor–Modified T Cells
Authors: Berger Carolina , Sommermeyer Daniel , Hudecek Michael , Berger Michael , Balakrishnan Ashwini , Paszkiewicz Paulina J. , Kosasih Paula L. , Rader Christoph , Riddell Stanley R.
Published: April 2023

Serum chemistry and cytokine levels in control animals.
Supplemental Figure Legend from Attenuated Toxoplasma gondii Stimulates Immunity to Pancreatic Cancer by Manipulation of Myeloid Cell Populations
Authors: Sanders Kiah L. , Fox Barbara A. , Bzik David J.
Published: April 2023

Supplemental Figure Legend from Attenuated Toxoplasma gondii Stimulates Immunity to Pancreatic Cancer by Manipulation of Myeloid Cell Populations
Supplemental Figure 7 from Attenuated Toxoplasma gondii Stimulates Immunity to Pancreatic Cancer by Manipulation of Myeloid Cell Populations
Authors: Sanders Kiah L. , Fox Barbara A. , Bzik David J.
Published: April 2023

No dependence on NK cells.
Supplemental Figure 5 from Attenuated Toxoplasma gondii Stimulates Immunity to Pancreatic Cancer by Manipulation of Myeloid Cell Populations
Authors: Sanders Kiah L. , Fox Barbara A. , Bzik David J.
Published: April 2023

Systemic T cell levels and regulatory T cells in the peritoneum.
Supplemental Figure 3 from Attenuated Toxoplasma gondii Stimulates Immunity to Pancreatic Cancer by Manipulation of Myeloid Cell Populations
Authors: Sanders Kiah L. , Fox Barbara A. , Bzik David J.
Published: April 2023

Systemic IL-12p40/p70 levels and intracellular IL-12p35 production.
Supplementary Figure 1 from Follicle-Stimulating Hormone Receptor as a Target in the Redirected T-cell Therapy for Cancer
Authors: Urbanska Katarzyna , Stashwick Caitlin , Poussin Mathilde , Powell Daniel J.
Published: April 2023

The expression of 18S used as a internal control (housekeeper). cDNA was constructed from total RNA isolated from 10e5 cells (cultured at 60-70% confluence). PCR performed using intron-spanning primers. Validation criteria included water blanks, and NO RT samples. For human 18SrRNA 5â€™CAGCCACCCGAGATTGAGCA3â€™ and Rev: 5â€™TAGTAGCGACGGGCGGTGTG3â€™ (amplicon 253bp) (Genbank:: NR_003286.2). For mouse ID8 cell line Ribosomal RNA for mouse Eukaryotic small ribosomal subunit [Genbank: NR_003278] primers Fw: 5â€™AGGGGAGAGCGGGTAAGAGA-3â€™ and Rev: 5â€™GGACAGGACTAGGCGGAACA3â€™ were used (amplicon size of 249bp).
Supplemental Table 5 from Molecular Programming of Tumor-Infiltrating CD8+ T Cells and IL15 Resistance
Authors: Doedens Andrew L. , Rubinstein Mark P. , Gross Emilie T. , Best J. Adam , Craig David H. , Baker Megan K. , Cole David J. , Bui Jack D. , Goldrath Ananda W.
Published: April 2023

PyMT tumor versus spleen fold change, acute infection day 6 versus spleen fold change.
Supplementary Table 1 and Supplementary Figures 1 and 2 from Lenalidomide Induces Interleukin-21 Production by T Cells and Enhances IL21-Mediated Cytotoxicity in Chronic Lymphocytic Leukemia B Cells
Authors: Browning Rebekah L. , Byrd William H. , Gupta Nikhil , Jones Jeffrey , Mo Xiaokui , Hertlein Erin , Yu Lianbo , Muthusamy Natarajan , Byrd John C.
Published: April 2023

This includes additional material for the paper including 1) Table 1. Microarray results for genes of interest; 2) Figure s1 showing decrease in IKZF1 and IKZF3 by lenalidomide; and Figure S2. Lenalidomide, IL-21, and the combination of lenalidomide + IL-21 induce different transcriptional signatures
Supplemental Table 3 from Molecular Programming of Tumor-Infiltrating CD8+ T Cells and IL15 Resistance
Authors: Doedens Andrew L. , Rubinstein Mark P. , Gross Emilie T. , Best J. Adam , Craig David H. , Baker Megan K. , Cole David J. , Bui Jack D. , Goldrath Ananda W.
Published: April 2023

PyMT tumor CD8+ versus day 5 effector OT-I gene expression and fold change.
Supplementary Table 1 from Therapeutic Peptide Vaccine-Induced CD8 T Cells Strongly Modulate Intratumoral Macrophages Required for Tumor Regression
Authors: van der Sluis Tetje C. , Sluijter Marjolein , van Duikeren Suzanne , West Brian L. , Melief Cornelis J.M. , Arens Ramon , van der Burg Sjoerd H. , van Hall Thorbald
Published: April 2023

RT-PCR primer sequences are compiled in this table.
Supplemental Figure S2 from Therapeutic Peptide Vaccine-Induced CD8 T Cells Strongly Modulate Intratumoral Macrophages Required for Tumor Regression
Authors: van der Sluis Tetje C. , Sluijter Marjolein , van Duikeren Suzanne , West Brian L. , Melief Cornelis J.M. , Arens Ramon , van der Burg Sjoerd H. , van Hall Thorbald
Published: April 2023

A) Wild-type C57BL/6 mice were injected s.c. with TC-1 tumor cells in the flank. Half of the mice received PLX chow, the other half control chow. Nine days later, when tumors were palpable, 50% of the mice in each group were treated with HPV16 E743-77 peptide in IFA in the opposing flank. Ten days later, on day 19 tumors were resected. Tumors were embedded in paraffin and stained for F4/80, as a marker for macrophages. Photos are representative for the whole tumor area and at least four samples per group.